Press-release for stocks for eli lilly and company

entities : Eli lilly and company

save search

Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy
Published: 2022-04-11 (Crawled : 12:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 140.87% | O: 0.45% H: 0.21% C: -1.32%
VERU | $1.305 -8.1% -8.81% 2.6M

Health Technology

| -67.36% | O: 37.7% H: 143.24% C: 105.01%
covid-19 drug sabizabulin phase 3

Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients
Published: 2022-04-25 (Crawled : 14:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 160.48% | O: -3.29% H: 2.58% C: 2.31%
VERU | $1.305 -8.1% -8.81% 2.6M

Health Technology

| -87.33% | O: 0.89% H: 27.06% C: 24.67%
covid-19 treatment sabizabulin presentation phase 2

Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3
Published: 2023-10-31 (Crawled : 10:00) - globenewswire.com
VERV | $6.65 -0.15% 860K

Professional, Scientific, and T...

| -28.37% | O: 5.31% H: 28.36% C: 21.49%
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 32.07% | O: -0.03% H: 0.0% C: 0.0%

Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
Published: 2021-01-27 (Crawled : 12:00) - globenewswire.com
GSK | $39.75 1.22% 0.0% 1.6M

Health Technology

| 0.92% | O: -1.12% H: 0.1% C: -1.6%
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 252.94% | O: -0.78% H: 0.45% C: -1.66%
VIR | $7.96 0.0% 1.1M

Health Technology

| -89.34% | O: -7.13% H: 96.21% C: 15.59%
covid ev biotech trial

AC Immune Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Published: 2021-08-04 (Crawled : 12:00) - globenewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 193.28% | O: 0.0% H: 5.72% C: 2.53%
BNTX | $86.82 0.75% 0.75% 1.6M

Health Technology

| -75.51% | O: 2.61% H: 20.19% C: 14.8%
ACIU | $2.355 -1.05% 18K

Health Technology

| -66.62% | O: -1.54% H: 4.56% C: 0.0%
financial results results

Veru Submits Emergency Use Authorization (EUA) Application to U.S. FDA for Sabizabulin, its Novel, Oral Antiviral and Anti-Inflammatory Drug Candidate for Hospitalized COVID-19 Patients at High Risk for ARDS
Published: 2022-06-07 (Crawled : 11:00) - globenewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 138.6% | O: -3.62% H: 0.0% C: 0.0%
VERU | $1.305 -8.1% -8.81% 2.6M

Health Technology

| -90.12% | O: -2.57% H: 17.21% C: 13.21%
covid-19 fda risk drug antiviral application authorization emergency use authorization

Veru Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published: 2022-11-10 (Crawled : 02:00) - globenewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 106.67% | O: 1.09% H: 0.48% C: 0.4%
VERU | $1.305 -8.1% -8.81% 2.6M

Health Technology

| -90.54% | O: -58.83% H: 25.89% C: 12.78%
covid-19 fda risk sabizabulin meeting respiratory authorization update

Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients
Published: 2022-07-06 (Crawled : 12:00) - globenewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 133.13% | O: 1.85% H: 1.45% C: 0.66%
VERU | $1.305 -8.1% -8.81% 2.6M

Health Technology

| -87.67% | O: 0.26% H: 20.43% C: 12.73%
covid-19 treatment sabizabulin trial results publication phase 3

Prelude Therapeutics Announces Appointment of Martin Babler to its Board of Directors
Published: 2021-07-19 (Crawled : 12:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 223.68% | O: -0.03% H: 1.04% C: 0.97%
SNY | News | $46.385 2.19% 3M

Health Technology

| -11.9% | O: -0.68% H: 0.41% C: -0.31%
PRLD | $3.685 7.12% 42K

Health Technology

| -85.45% | O: -2.4% H: 15.87% C: 11.88%

Innovent Releases the Phase Ia/Ib Dose-Escalation Trial Results of IBI110 (anti-LAG-3) in Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
Published: 2021-06-07 (Crawled : 01:00) - prnewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 271.63% | O: -0.01% H: 15.52% C: 10.16%
solid tumors results trial trial results

Innovent and HUTCHMED Release Phase 1b preliminary Results of TYVYT (Sintilimab Injection) plus Fruquintinib as a Third Line Treatment for Advanced Colorectal Cancer at ASCO Annual Meeting 2021
Published: 2021-06-07 (Crawled : 01:00) - prnewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 271.63% | O: -0.01% H: 15.52% C: 10.16%
treatment phase 1 injection results cancer colorectal cancer phase 1b phase 2b

Innovent and AnHeart Release Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting
Published: 2021-06-07 (Crawled : 01:00) - prnewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 271.63% | O: -0.01% H: 15.52% C: 10.16%
heart positive results trial

AnHeart and Innovent Releases Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting
Published: 2021-06-07 (Crawled : 07:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 271.63% | O: -0.01% H: 15.52% C: 10.16%
heart positive results trial

DTx Pharma Appoints Jill Howe as Chief Financial Officer
Published: 2021-06-07 (Crawled : 12:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 271.63% | O: -0.01% H: 15.52% C: 10.16%
pharma

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M

Health Technology

| -10.4% | O: -0.21% H: 0.11% C: -1.06%
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 2.23% | O: 0.9% H: 2.03% C: 1.89%
VERU | $1.305 -8.1% -8.81% 2.6M

Health Technology

| 115.81% | O: -0.53% H: 2.22% C: -3.59%
ALT | $6.91 0.29% 0.29% 3.6M

Commercial Services

| -30.19% | O: 0.3% H: 11.41% C: 9.8%
medical program

Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023
Published: 2023-09-20 (Crawled : 13:00) - globenewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 30.58% | O: -0.21% H: 0.0% C: 0.0%
VERU | $1.305 -8.1% -8.81% 2.6M

Health Technology

| 71.81% | O: 1.63% H: 11.9% C: 9.23%
conference global

Innovent and Bolt Biotherapeutics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs
Published: 2021-08-27 (Crawled : 01:00) - prnewswire.com
BOLT | $1.11 -2.63% 54K

| -92.7% | O: 0.63% H: 10.0% C: 9.02%
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 187.3% | O: 0.33% H: 0.0% C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M

Health Technology

| -29.71% | O: -0.03% H: 0.0% C: 0.0%
collaboration iot announces collaboration

New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials
Published: 2021-05-04 (Crawled : 12:00) - biospace.com/
ABCL | $3.88 -0.77% -0.77% 980K

| -84.42% | O: -0.65% H: 10.38% C: 8.4%
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 303.81% | O: 0.87% H: 1.36% C: 0.36%
covid clinical trials antibody trial covid-19

Veru Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results
Published: 2022-12-05 (Crawled : 12:00) - globenewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology

| 100.33% | O: -0.27% H: 0.4% C: -1.2%
VERU | $1.305 -8.1% -8.81% 2.6M

Health Technology

| -74.18% | O: -1.82% H: 20.93% C: 7.78%
year financial results

HUTCHMED Reports 2021 Interim Results and Provides Business Updates
Published: 2021-07-28 (Crawled : 12:00) - globenewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M

Health Technology